Verona Pharma
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 79
- Market Cap
- -
- Website
- http://www.veronapharma.com
- Introduction
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Verona Pharma will report Q3 2024 financial results on Nov 4, hosting a conference call at 9:00 a.m. EDT / 2:00 p.m. GMT. The call can be joined via phone or webcast on the company's website, with a replay available for 90 days.
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs
GSK's MATINEE Phase 3 trial showed Nucala (mepolizumab) significantly reduced COPD exacerbations in type 2 inflammation patients, with safety consistent with known profile. Nucala is not yet indicated for COPD but contributed 6% to GSK's 2023 sales.
© Copyright 2024. All Rights Reserved by MedPath